117 related articles for article (PubMed ID: 32522096)
1. Bevacizumab-Conjugated Quantum Dots:
Santana CP; Mansur AAP; Mansur HS; Silva-Cunha AD
J Ocul Pharmacol Ther; 2020; 36(6):467-483. PubMed ID: 32522096
[No Abstract] [Full Text] [Related]
2. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.
Liu J; Zhang X; Li G; Xu F; Li S; Teng L; Li Y; Sun F
Int J Nanomedicine; 2019; 14():8819-8834. PubMed ID: 31819410
[TBL] [Abstract][Full Text] [Related]
3. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.
Inan UU; Avci B; Kusbeci T; Kaderli B; Avci R; Temel SG
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1773-81. PubMed ID: 17389511
[TBL] [Abstract][Full Text] [Related]
4. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
[TBL] [Abstract][Full Text] [Related]
5. Effects of anti-VEGF agents on rat retinal Müller glial cells.
Guo B; Wang Y; Hui Y; Yang X; Fan Q
Mol Vis; 2010 May; 16():793-9. PubMed ID: 20454698
[TBL] [Abstract][Full Text] [Related]
6. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
[TBL] [Abstract][Full Text] [Related]
7. Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes.
Xu W; Wang H; Wang F; Jiang Y; Zhang X; Wang W; Qian J; Xu X; Sun X
Can J Ophthalmol; 2010 Aug; 45(4):386-92. PubMed ID: 20648082
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice.
Heiduschka P; Julien S; Hofmeister S; Bartz-Schmidt KU; Schraermeyer U
Retina; 2008 Jan; 28(1):46-55. PubMed ID: 18185137
[TBL] [Abstract][Full Text] [Related]
9. Corosolic acid: antiangiogenic activity and safety of intravitreal injection in rats eyes.
Toledo CR; Pereira VV; Dourado LFN; Paiva MRB; Silva-Cunha A
Doc Ophthalmol; 2019 Jun; 138(3):181-194. PubMed ID: 30809742
[TBL] [Abstract][Full Text] [Related]
10. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab.
Wittström E; Holmberg H; Hvarfner C; Andréasson S
Eur J Ophthalmol; 2012; 22(4):563-74. PubMed ID: 22139613
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Sasamoto Y; Oshima Y; Miki A; Wakabayashi T; Song D; Matsushita K; Hamasaki T; Nishida K
J Ocul Pharmacol Ther; 2012 Feb; 28(1):41-8. PubMed ID: 21992534
[TBL] [Abstract][Full Text] [Related]
14. Licarin A as a Novel Drug for Inflammatory Eye Diseases.
Paiva MRB; Vasconcelos-Santos DV; Coelho MM; Machado RR; Lopes NP; Silva-Cunha A; Fialho SL
J Ocul Pharmacol Ther; 2021 Jun; 37(5):290-300. PubMed ID: 33761287
[No Abstract] [Full Text] [Related]
15. Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits.
Hu CC; Chiu YC; Chaw JR; Chen CF; Liu HW
Technol Health Care; 2019; 27(S1):153-163. PubMed ID: 31045535
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma].
Ishibashi S; Kondo H
J UOEH; 2015 Dec; 37(4):299-304. PubMed ID: 26667197
[TBL] [Abstract][Full Text] [Related]
17. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.
Ziemssen F; Lüke M; Messias A; Beutel J; Tatar O; Zrenner E; Bartz-Schmidt KU;
Int Ophthalmol; 2008 Apr; 28(2):101-9. PubMed ID: 17634860
[TBL] [Abstract][Full Text] [Related]
18. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab in the treatment of diabetic ocular neovascularization.
Ababneh OH; Yousef YA; Gharaibeh AM; Abu Ameerh MA; Abu-Yaghi NE; Al Bdour MD
Retina; 2013 Apr; 33(4):748-55. PubMed ID: 23296048
[TBL] [Abstract][Full Text] [Related]
20. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
